Epcoritamab plus lenalidomide cut progression risk by 60% in R/R DLBCL in a phase 3 trial. Five-year AUGMENT follow-up supports R2 in indolent NHL; a phase 2 penpulimab-lenalidomide-R-GemOx trial showed activity in DLBCL.
BMS's mezigdomide doubled progression-free survival in relapsed/refractory multiple myeloma at ASCO, while the FDA reviews iberdomide with a decision due by August 17. C4 Therapeutics has dosed the first patient in its Phase 2 MOMENTUM trial of cemsidomide.
European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.
Genmab is moving GEN1106, a SLITRK6-targeting ADC acquired through its $1.8bn ProfoundBio takeover, into phase 1 trials despite several recent discontinuations and the 2017 failure of the only other similar project.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07714421 |
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients |
NOT_YET_RECRUITING | PHASE1 |
| NCT07702032 |
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer |
RECRUITING | PHASE3 |
| NCT07695831 |
A Phase 1 Trial of GEN1119 in Participants With Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT07604766 |
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China |
NOT_YET_RECRUITING | PHASE3 |
| NCT07564141 |
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer |
RECRUITING | PHASE3 |
| NCT07539311 |
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers |
RECRUITING | PHASE2 |
| NCT07416123 |
A Study of GEN1106 in Participants With Solid Tumors |
RECRUITING | PHASE1 |
| NCT07387068 |
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT07384715 |
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) |
RECRUITING | PHASE1 |
| NCT07288177 |
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer |
RECRUITING | PHASE2 |
